L. Wood

Durable Responses and Low Toxicity After Fast Off-Rate CD19 Chimeric Antigen Receptor-T Therapy in Adults With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia

M. Abbasian, K. Peggs, F. Farzaneh, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Limited efficacy of APRIL CAR in patients with multiple myeloma indicate challenges in the use of natural ligands for CAR T-cell therapy

R. Reijmers, M. Al-Hajj, S. Onuoha, 2023, Journal for immunotherapy of cancer.

ALLCAR19: Updated Data Using AUTO1, a Novel Fast-Off Rate CD19 CAR in Relapsed/Refractory B-Cell Acute Lymphoblastic Leukaemia and Other B-Cell Malignancies

M. Abbasian, K. Peggs, F. Farzaneh, 2020 .

Dual targeting of CD19 and CD22 with bicistronic CAR-T cells in patients with relapsed/refractory large B-cell lymphoma

E. Tholouli, K. Ardeshna, K. Peggs, 2023, Blood.

Limited efficacy of APRIL CAR in patients with multiple myeloma indicate challenges in the use of natural ligands for CAR T-cell therapy

R. Reijmers, M. Al-Hajj, K. Yong, 2023, Journal for ImmunoTherapy of Cancer.

Becker Digital

E. Tholouli, K. Ardeshna, L. Lekakis, 2022 .

Automated Manufacture of Matched Donor-Derived Allogeneic CD19 CAR T-Cells for Relapsed/Refractory B-ALL Following Allogeneic Stem Cell Transplantation: Toxicity, Efficacy and the Important Role of Lymphodepletion

M. Abbasian, K. Peggs, F. Farzaneh, 2019, Blood.